SCHEDULE 13G: State Street Corporation Discloses 5.1% Passive Stake in Arrowhead Pharmaceuticals
Beneficial Ownership Disclosure
State Street Corporation has filed a Schedule 13G, revealing a 5.1% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. as of March 31, 2025.
Summary
- State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G with the SEC.
- The filing indicates that State Street Corporation beneficially owns 6,999,249 shares of Arrowhead Pharmaceuticals Inc. common stock.
- This aggregate amount represents 5.1% of Arrowhead Pharmaceuticals Inc.'s outstanding common stock.
- State Street Corporation holds shared voting power over 6,575,768 shares and shared dispositive power over 6,999,249 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Arrowhead Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's operational performance or future prospects. It is a neutral, compliance-driven filing.
Positives
- The disclosure of a significant 5.1% stake by a major institutional investor like State Street Corporation may be viewed by some as a vote of confidence in Arrowhead Pharmaceuticals Inc.
Negatives
- The Schedule 13G filing is a factual disclosure of ownership and does not inherently contain negative information regarding the issuer's performance or outlook.
Risks
- NA
Future Outlook
NA
Industry Context
This filing reflects a standard institutional investment disclosure, indicating a large asset manager's passive stake in a pharmaceutical company. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact of the investment itself.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holding may provide a degree of confidence or stability, indicating that a major financial entity sees value in holding the company's stock.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement, representing the reporting period end for the beneficial ownership. |
| 05/09/2025 | Date the Schedule 13G statement was signed by State Street Corporation. |
Keywords
Arrowhead Pharmaceuticals, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.